Gritstone Oncology (GRTS) Reaches New 12-Month High at $30.41

Gritstone Oncology Inc (NASDAQ:GRTS) reached a new 52-week high during trading on Thursday . The stock traded as high as $30.41 and last traded at $31.08, with a volume of 2783 shares trading hands. The stock had previously closed at $30.23.

Several research firms have recently commented on GRTS. BTIG Research began coverage on shares of Gritstone Oncology in a research report on Tuesday, October 23rd. They set a “buy” rating and a $26.00 price target for the company. Barclays assumed coverage on shares of Gritstone Oncology in a report on Tuesday, October 23rd. They issued an “overweight” rating and a $25.00 target price for the company. Cowen assumed coverage on shares of Gritstone Oncology in a report on Tuesday, October 23rd. They issued an “outperform” rating for the company. Finally, Goldman Sachs Group assumed coverage on shares of Gritstone Oncology in a report on Tuesday, October 23rd. They issued a “neutral” rating and a $18.00 target price for the company.

Gritstone Oncology (NASDAQ:GRTS) last released its earnings results on Wednesday, November 14th. The company reported ($7.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($6.97). The company had revenue of $0.10 million for the quarter.

In other news, Director Nicholas Simon bought 333,333 shares of Gritstone Oncology stock in a transaction that occurred on Friday, September 28th. The stock was bought at an average cost of $15.00 per share, with a total value of $4,999,995.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

A number of institutional investors have recently added to or reduced their stakes in GRTS. Victory Capital Management Inc. purchased a new stake in Gritstone Oncology in the 3rd quarter worth approximately $1,424,000. Wells Fargo & Company MN purchased a new stake in Gritstone Oncology in the 3rd quarter worth approximately $578,000. JPMorgan Chase & Co. purchased a new stake in Gritstone Oncology in the 3rd quarter worth approximately $2,065,000. Asymmetry Capital Management L.P. purchased a new stake in Gritstone Oncology in the 3rd quarter worth approximately $285,000. Finally, Alliancebernstein L.P. purchased a new stake in Gritstone Oncology in the 3rd quarter worth approximately $285,000. 43.52% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.com-unik.info/2018/12/08/gritstone-oncology-grts-reaches-new-12-month-high-at-30-41.html.

Gritstone Oncology Company Profile (NASDAQ:GRTS)

Gritstone Oncology Inc is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc has a strategic collaboration with bluebird bio, Inc The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.

Read More: Hedge Funds Explained

Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit